Respiratory

Latest News

Nerandomilast is an investigational oral, preferential inhibitor of phosphodiesterase 4B that has shown promise in IPF and PPF. | Image credit: Елена Бутусова - stock.adobe.com
Nerandomilast Improves Lung Function in Progressive Pulmonary Fibrosis: FIBRONEER-ILD

February 13th 2025

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline at 52 weeks in the phase 3 FIBRONEER-ILD trial.

Sanofi | Image credit: Eagle - stock.adobe.com
Combination Influenza and COVID-19 Vaccine Candidates Granted Fast Track Designation

December 16th 2024

Group of diverse kids | Image Credit: © EKKAPON-stock.adobe.com
Ambient Toxins Linked to Disabilities in Minority Schoolchildren

December 10th 2024

RSV vaccine | Image credit: Pawel - atock.adobe.com
Nirsevimab Protected Infants, Children From Severe RSV in 2023–2024 Season

December 6th 2024

Doctor with an image of lungs | Image credit: lungs_PRASANNAPIX
Key Flu and RSV Recommendations for the 2024-2025 Respiratory Virus Season

November 26th 2024

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo